Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes.
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia found in clinical practice. AF rarely exists as a single entity but rather as part of a diverse clinical spectrum of cardiovascular diseases, related to structural and electrical remodeling within the left atrium, leading to AF onset, perpetuation, and progression. Due to the high overall prevalence within the AF population arterial hypertension plays a significant role in the pathogenesis of AF and its complications. Fibroblast proliferation, apoptosis of cardiomyocytes, gap junction remodeling, accumulation of collagen both in atrial and ventricular myocardium all accompany ageing-related structural remodeling with impact on electrical activity. The presence of hypertension also stimulates oxidative stress, systemic inflammation, rennin-angiotensin-aldosterone and sympathetic activation, which further drives the remodeling process in AF. Importantly, both hypertension and AF independently increase the risk of cardiovascular and cerebrovascular events, e.g., stroke and myocardial infarction. Given that both AF and hypertension often present with limited on patient wellbeing, treatment may be delayed resulting in development of complications as the first clinical manifestation of the disease. Antithrombotic prevention in AF combined with strict blood pressure control is of primary importance, since stroke risk and bleeding risk are both greater with underlying hypertension.
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.|Grodno State Medical University, Grodno, Belarus.
Mikhail S
MS
Dzeshka
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
Farhan
F
Shahid
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
Alena
A
Shantsila
University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.|Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Gregory Y H
GYH
Lip
D001281:Atrial Fibrillation / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology*; D064752:Atrial Remodeling; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology*; D011379:Prognosis; D016896:Treatment Outcome
aging; atrial fibrillation; bleeding; blood pressure; epidemiology; fibrosis; hypertension; inflammation; oxidative stress; prevention; stroke